Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 19, 2026

Procter & Gamble Q2 Earnings Preview: Buy Now or Stay Cautious?

View original at finance.yahoo.com
Procter & Gamble Q2 Earnings Preview: Buy Now or Stay Cautious? The Procter & Gamble Company PG, also known as P&G, is set to report second-quarter fiscal 2026 results on Jan…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Management predicts a commodity cost headwind of $100 million after tax for fiscal 2026

    80% confidence
  • Management anticipates an after-tax headwind of about $250 million for fiscal 2026 due to modestly higher net interest expenses and an increased core effective tax rate compared with the previous year

    80% confidence
  • Our model estimates organic sales growth of 2% each for the Beauty and Health Care segments, and 4% for the Grooming segment

    80% confidence
  • Procter & Gamble has an Earnings ESP of -0.82% and a Zacks Rank #4 (Sell)

    80% confidence
  • Management cautioned that tariff relief may be offset by pricing rollbacks if duties are reduced

    80% confidence
  • The consensus mark for earnings has moved down by a penny in the past 30 days

    80% confidence
  • Management repeatedly emphasizing that sustainable growth will come from superior performance rather than price-led tactics

    80% confidence
  • For new investors, waiting for clearer signs of margin recovery or a more attractive valuation could be prudent

    80% confidence
  • Existing shareholders may consider holding the stock for its stability and long-term fundamentals, while closely monitoring execution on innovation, pricing and productivity initiatives

    80% confidence
  • We expect organic sales for both the Fabric & Home Care, and and Baby, Feminine & Family Care segments to be flat year over year

    80% confidence
  • PG has a trailing four-quarter earnings surprise of 2.3%, on average

    80% confidence
  • Our model predicts a year-over-year core gross margin decline of 50 bps for the fiscal second quarter

    80% confidence
  • The consensus mark for PG's earnings is pegged at $1.87 per share, indicating a 0.5% decline from the year-ago quarter's actual

    80% confidence
  • Our model predicts year-over-year organic sales growth of 1% for PG in the second quarter of fiscal 2026

    80% confidence
  • We expect the core operating margin to fall by 80 bps in the quarter

    80% confidence
  • Management expects higher costs from tariffs of $400 million, after-tax, for fiscal 2026

    80% confidence
  • The Zacks Consensus Estimate for fiscal second-quarter revenues is pegged at $22.23 billion, indicating a 1.6% rise from the prior-year quarter's reported figure

    80% confidence
  • Management acknowledged heightened promotional activity in categories, such as Fabric Care, Baby Care and Oral Care, particularly in the United States and Europe

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com
Procter & Gamble Q2 Earnings Preview: Buy Now or Stay Cautious? — Source | Via News | ViaNews Market